Q-omics provides the consensus-scored ZFAND6 profile across patient tissues and cancer cell-line models. ZFAND6 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, ZFAND6 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, ZFAND6 RNA expression shows 20,125 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LGG, HNSC, and ACC as cancer lineages where ZFAND6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZFAND6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZFAND6 survival associations across molecular data types. ZFAND6 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZFAND6 RNA expression–survival associations across cancer types. High ZFAND6 expression shows unfavorable associations in LGG, ACC, UVM and PAAD, but favorable associations in KIRC and SKCM. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for ZFAND6 RNA expression.
This table summarizes ZFAND6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ZFAND6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZFAND6 shows lower tumor expression in KICH and READ and higher tumor expression in HNSC, LIHC, BRCA and CHOL. The HNSC box plot shows higher ZFAND6 RNA expression in tumor versus normal tissue (log2 FC = +0.626, t-test p < 0.001).
This table shows molecular features associated with ZFAND6 in patient tissues and cancer cell lines. In patient samples, ZFAND6 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZFAND6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
